Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLGA trial of capecitabine + bevacizumab with radiotherapy in oligometastatic colorectal cancer
2011-005296-16Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and bevacizumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Progression-free survival rate at 12 months after start of induction treatment. Started Jun 2012; status: terminated.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2011-005296-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005296-16.